Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:52 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing that patients receiving the custom treatment with Keytruda went longer without cancer recurrence than those on Keytruda alone. This is a material positive catalyst for Moderna, as evidenced by the 177% stock surge.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:47 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. The stock surged 177% on the news, indicating a strong positive catalyst.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:42 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a significant positive catalyst that led to a 177% surge in its stock price.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:37 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing that patients receiving the custom treatment plus Keytruda went longer without cancer recurrence. This is a significant positive development for the company, and the stock surged 177% on the news.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:32 PM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares surged 177% on the news, indicating a strong positive market reaction and improved expected fundamentals.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:27 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:22 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company's fundamentals and future prospects.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:17 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:12 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, showing improved recurrence-free survival when combined with Keytruda. The stock surged 177% on the news, indicating a strong positive market reaction and improved expected fundamentals.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 09:07 PM UTC

Moderna and Merck reported positive Phase 3 results for their personalized cancer treatment, showing that patients receiving the custom shot plus Keytruda went longer without cancer recurrence than those on Keytruda alone. This is a significant clinical milestone and a material positive catalyst for Moderna, as reflected in the 177% stock surge.